# Evaluation of Omarigliptin (MK-3102) in Obese Participants and in Participants With Type 2 Diabetes (MK-3102-004)

> **NCT01088711** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 32 (actual)

## Conditions studied

- Type 2 Diabetes (T2D)

## Interventions

- **DRUG:** Omarigliptin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01088711
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-03-11
- **Primary completion:** 2010-05-11
- **Final completion:** 2010-05-11
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2018-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01088711

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01088711, "Evaluation of Omarigliptin (MK-3102) in Obese Participants and in Participants With Type 2 Diabetes (MK-3102-004)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01088711. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*